BioCentury
ARTICLE | Targets & Mechanisms

Placing kinases in the WNT pathway

March 14, 2013 7:00 AM UTC

Despite the well-established role of WNT signaling in many cancers, the pathway has proven difficult to modulate therapeutically because it is largely composed of hard-to-target protein-protein interactions. Now, a Boston-based team and a group led by Roche's Genentech Inc. unit have each identified a new kinase regulator of WNT signaling-YES1 and RIPK4, respectively-that provide two new druggable targets in the pathway.1,2

Each team will now look for the cancer subtypes most likely to respond to inhibitors of these kinases...